Daily AI-curated articles on clinical trials, FDA updates, and pharmaceutical insights.
The FDA's approval of Foundayo (orforglipron) marks the fifth success under the National Priority Voucher pilot program, potentially accelerating future diabetes treatments.
FDA alerts clinical professionals about differential pressure sensor malfunctions in Abiomed Impella RP devices, prompting updated usage instructions for safer patient care.
New cardiovascular research study in Covina, CA seeks participants with established heart disease diagnosis. Study design allows continuation of existing treatments.
UK's NICE approves Wegovy for cardiovascular protection beyond weight loss, marking significant expansion in semaglutide's therapeutic applications for clinical research.
FDA approves tividenofusp alfa-eknm (Avlayah) for neurologic manifestations of Hunter syndrome, marking a significant milestone in MPS II treatment.
Cardinal Health recalls Webcol alcohol prep pads due to Paenibacillus phoenicis contamination, raising critical sterile procedure concerns for clinical research sites.
New clinical trial in Gainesville, FL investigates one-time minimally invasive procedure for patients with uncontrolled blood pressure despite triple therapy.
Daiichi Sankyo and AstraZeneca's Enhertu receives additional regulatory approvals in Japan, marking significant progress for the ADC therapy in expanding clinical applications.
